【私募调研记录】高毅资产调研惠泰医疗

Group 1 - Gao Yi Asset recently conducted research on Hui Tai Medical, focusing on strategies to address tariff issues by forming specialized teams to achieve self-supply of key raw materials, thereby reducing reliance on foreign procurement [1] - Hui Tai Medical's ODM business benefits from upstream material control, while its OEM business continues to grow, with stable production capacity in the weaving workshop [1] - The company has resolved key application issues with PFA technology, and its sales team covers both RFA and PFA businesses, with a promotion strategy centered on PF [1] - There is significant growth potential in the domestic and international vascular intervention markets, with plans for gradual automation in production [1] - The company has no immediate plans for increased investment in neuro-intervention, but has clear development plans for overseas brands, expecting international business growth to outpace domestic growth [1] - Hui Tai Medical aims to become a top-tier global player in the cardiovascular field, focusing on strengthening management systems and team building, while expanding the application of PF technology platforms [1] - The company needs to enhance its operational platform, with clear targets set for electrophysiological procedures, and a compound growth rate for atrial fibrillation expected to maintain around 15% [1]